Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating Combination of TST001, Pembrolizumab and Chemotherapy as First-Line Treatment in Subjects With Claudin18.2 Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

NCT06093425 is registered in ClinicalTrials.gov with Transcenta Therapeutics (Hangzhou) Co., Ltd. as lead sponsor.

NCT NCT06093425
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06093425 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating Combination of TST001, Pembrolizumab and Chemotherapy as First-Line Treatment in Subjects With Claudin18.2 Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
Lead sponsor
Transcenta Therapeutics (Hangzhou) Co., Ltd.
Phase
Phase 3
Overall status
Not yet recruiting
Start date
June 30, 2027
Completion date
January 31, 2030
Enrollment
820 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, gastric cancer, gastroesophageal-junction cancer